Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Lecanemab Reduces Cognitive Decline in Alzheimer’s
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Parkinson Disease
Dr. Cook gives an overview of symptoms and treatment of Parkinson Disease.
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Aducanumab Update
While various opinions are circulating, and the benefits of this drug are unclear, ANA will continue to monitor the situation and provide updates as information becomes available.
How to Get a Good Night’s Sleep
Establishing good sleep habits is the first step to improving your sleep quality.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Trailblazer clinical trial featured in New York Times
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
Trailblazer clinical trial featured in New England Journal of Medicine
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
